BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cervical Cancer readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Cervical Cancer\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06640283-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06640283)
DESCRIPTION:Pembrolizumab\, phase 2\, Cervical Cancer.\nStudy: Dynamic ctDN
 A Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and C
 linical Outcomes\nEstimated primary completion: December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06640283
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07143292-1972@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07143292)
DESCRIPTION:Camrelizumab\, phase 2\, Cervical Cancer.\nStudy: A Prospective
 \, Randomized\, Parallel Trial of Famitinib Malate at Different Doses Comb
 ined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervi
 cal Cancer\nEstimated primary completion: 30 December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07143292
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07143292-2035@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Famitinib: Phase 2 readout est. (NCT07143292)
DESCRIPTION:Famitinib\, phase 2\, Cervical Cancer.\nStudy: A Prospective\, 
 Randomized\, Parallel Trial of Famitinib Malate at Different Doses Combine
 d With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical
  Cancer\nEstimated primary completion: 30 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/famitinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07143292
URL:https://assetmemo.bio/drug/famitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140526-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04140526)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety\, PK and Efficacy of ONC-392 in Monotherapy and in Combination of 
 Anti-PD-1 in Advanced Solid Tumors and NSCLC\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04140526
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07167160-1972@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07167160)
DESCRIPTION:Camrelizumab\, phase 2\, Cervical Cancer.\nStudy: Chemo-immunot
 herapy for Cervical Cancer Stage IIICp Trial\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 amrelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07167160
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07104149-1994@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07104149)
DESCRIPTION:Cadonilimab\, phase 2\, Cervical Cancer.\nStudy: Neoadjuvant Ch
 emotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer\nEstimate
 d primary completion: 31 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07104149
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, G
 lioblastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion
 : 28 February 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06047379
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-2008@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 afety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Gli
 oblastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 
 28 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bev
 acizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06047379
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07054567-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07054567)
DESCRIPTION:Pembrolizumab\, phase 2\, Cervical Cancer.\nStudy: A Study of B
 L-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metas
 tatic Cervical Cancer and Endometrial Cancer\nEstimated primary completion
 : May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07054567
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07054567-2008@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07054567)
DESCRIPTION:Bevacizumab\, phase 2\, Cervical Cancer.\nStudy: A Study of BL-
 B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metasta
 tic Cervical Cancer and Endometrial Cancer\nEstimated primary completion: 
 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 54567
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02628067-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT02628067)
DESCRIPTION:Pembrolizumab\, phase 2\, Cervical Cancer.\nStudy: Study of Pem
 brolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-1
 58/KEYNOTE-158)\nEstimated primary completion: 4 May 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT02628067
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05081609-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05081609)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alo
 ne or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or 
 Other Anticancer Therapies in Adult Participants With Locally Advanced or 
 Metastatic Solid Tumor Malignancies\nEstimated primary completion: August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05081
 609
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07080216-2008@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07080216)
DESCRIPTION:Bevacizumab\, phase 1/2\, Cervical Cancer.\nStudy: Study of ZG0
 05 in Combination With Gecacitinib in Participants With Advanced Cervical 
 Cancer\nEstimated primary completion: August 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07080216
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07627620-1972@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07627620)
DESCRIPTION:Camrelizumab\, phase 2\, Cervical Cancer.\nStudy: Camrelizumab 
 Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent
 / Metastatic Cervical Cancer\nEstimated primary completion: 30 September 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0762762
 0
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07627620-2035@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Famitinib: Phase 2 readout est. (NCT07627620)
DESCRIPTION:Famitinib\, phase 2\, Cervical Cancer.\nStudy: Camrelizumab Com
 bined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ M
 etastatic Cervical Cancer\nEstimated primary completion: 30 September 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/famitinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07627620
URL:https://assetmemo.bio/drug/famitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07497074-2008@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07497074)
DESCRIPTION:Bevacizumab\, phase 2\, Cervical Cancer.\nStudy: JSKN033 Combin
 ation Therapy in Subjects With Advanced Cervical Cancer\nEstimated primary
  completion: October 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07497074
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06079671-1985@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20271126
DTEND;VALUE=DATE:20271127
SUMMARY:Volrustomig: Phase 3 readout est. (NCT06079671)
DESCRIPTION:Volrustomig\, phase 3\, Cervical Cancer.\nStudy: Study of Volru
 stomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Ce
 rvical)\nEstimated primary completion: 26 November 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/volrustomig#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06079671
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04865887-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04865887)
DESCRIPTION:Pembrolizumab\, phase 2\, Cervical Cancer.\nStudy: Pembrolizuma
 b and Lenvatinib in Advanced Cervical Cancer\nEstimated primary completion
 : December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemb
 rolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04865887
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07418749-2064@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Notiretatug rezetecan: Phase 3 readout est. (NCT07418749)
DESCRIPTION:Notiretatug rezetecan\, phase 3\, Cervical Cancer.\nStudy: A St
 udy of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients 
 With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Re
 current or Metastatic Cervical Cancer\nEstimated primary completion: Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/notiretatug
 -rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07418749
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05438420-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05438420)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Cervical Cancer.\nStudy: Oral Axl/M
 er/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pemb
 rolizumab in Patients With Selected Advanced Solid Tumors\nEstimated prima
 ry completion: 30 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05438420
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998394-1994@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06998394)
DESCRIPTION:Cadonilimab\, phase 2\, Cervical Cancer.\nStudy: A Single-Arm\,
  Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in
  Oligometastatic Stage IVB Cervical Cancer\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cad
 onilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06998394
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07348861-1991@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07348861)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Cervical Cancer.\nStudy: A 
 Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With 
 Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer\nEstimate
 d primary completion: 1 January 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07348861
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230626-10784@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Sutantatug envedotin: Phase 3 readout est. (NCT07230626)
DESCRIPTION:Sutantatug envedotin\, phase 3\, Cervical Cancer.\nStudy: SYS60
 02 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer\nEstimated p
 rimary completion: 1 January 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sutantatug-envedotin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07230626
URL:https://assetmemo.bio/drug/sutantatug-envedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943833-1985@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20280313
DTEND;VALUE=DATE:20280314
SUMMARY:Volrustomig: Phase 2 readout est. (NCT06943833)
DESCRIPTION:Volrustomig\, phase 2\, Cervical Cancer.\nStudy: A Study of Vol
 rustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)
 \nEstimated primary completion: 13 March 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/volrustomig#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06943833
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05269381-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05269381)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrol
 izumab for Treatment of Advanced Solid Tumors\nEstimated primary completio
 n: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05269381
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06459180-1991@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06459180)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Cervical Cancer.\nStudy: A 
 Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Trea
 tment of Physician's Choice as Second-line Treatment for Participants With
  Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101
 /ENGOT-cx20)\nEstimated primary completion: 15 June 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06459180
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04977453-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04977453)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or 
 Lenvatinib in Advanced Solid Tumors\nEstimated primary completion: 30 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0497
 7453
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04977453-2494@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:GI-101A: Phase 1/2 readout est. (NCT04977453)
DESCRIPTION:GI-101A\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: GI-10
 1/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvat
 inib in Advanced Solid Tumors\nEstimated primary completion: 30 June 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/gi-101a#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04977453
URL:https://assetmemo.bio/drug/gi-101a#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07256236-1991@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07256236)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Cervical Cancer.\nStudy: SK
 B264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer\nEstimated pri
 mary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07256236
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05086692-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05086692)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Beta-only IL-2 ImmunoTherapY Study\nEstimated primary completion: 20 Oc
 tober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05086692
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06535607-1985@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Volrustomig: Phase 2 readout est. (NCT06535607)
DESCRIPTION:Volrustomig\, phase 2\, Cervical Cancer.\nStudy: Study of Volru
 stomig as Monotherapy or in Combination With Anti- Cancer Agents in Partic
 ipants With Advanced/Metastatic Solid Tumors\nEstimated primary completion
 : 30 November 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/v
 olrustomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06535607
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05579366-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05579366)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Rinatabart Sesutecan (Rina-S\, PRO1184\, GEN1184) for Advanced Solid Tumo
 rs (GCT1184-01/ PRO1184-001)\nEstimated primary completion: December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05579366
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05579366-2008@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05579366)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: R
 inatabart Sesutecan (Rina-S\, PRO1184\, GEN1184) for Advanced Solid Tumors
  (GCT1184-01/ PRO1184-001)\nEstimated primary completion: December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05579366
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07649174-1994@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07649174)
DESCRIPTION:Cadonilimab\, phase 2\, Cervical Cancer.\nStudy: Cadonilimab Pl
 us Chemotherapy in LACC: A Prospective\, Multicenter\, Randomized Phase II
  Trial\nEstimated primary completion: 31 December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07649174
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07035808-2008@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07035808)
DESCRIPTION:Bevacizumab\, phase 2\, Cervical Cancer.\nStudy: a Single Arm\,
  Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety o
 f the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherap
 y ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherap
 y in Patients With Advanced Cervical Cancer .\nEstimated primary completio
 n: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07035808
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07450963-1994@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07450963)
DESCRIPTION:Cadonilimab\, phase 2\, Cervical Cancer.\nStudy: Cadonilimab Co
 mbined With RT in LACC Patients Ineligible for CCRT\nEstimated primary com
 pletion: February 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/cadonilimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07450963
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06981858-2291@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Enlonstobart: Phase 2 readout est. (NCT06981858)
DESCRIPTION:Enlonstobart\, phase 2\, Cervical Cancer.\nStudy: A Single-Arm 
 Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Ch
 emoradiotherapy for Locally Advanced Cervical Cancer\nEstimated primary co
 mpletion: 1 February 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/enlonstobart#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06981858
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Q
 UILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Pr
 eviously Received Treatment With Immune Checkpoint Inhibitors\nEstimated p
 rimary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07368985-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07368985)
DESCRIPTION:Pembrolizumab\, phase 2\, Cervical Cancer.\nStudy: Pembrolizuma
 b and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
 \nEstimated primary completion: October 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07368985
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05187338-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20291030
DTEND;VALUE=DATE:20291031
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05187338)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors\n
 Estimated primary completion: 30 October 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05187338
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976021-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06976021)
DESCRIPTION:Pembrolizumab\, phase 2\, Cervical Cancer.\nStudy: Immune PET a
 nd Proteomics for the Assessment of Response to Spatially Fractionated or 
 Palliative Radiotherapy With or Without Immunotherapy\nEstimated primary c
 ompletion: December 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06976021
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223424-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07223424)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 atient Preference for Subcutaneous vs. Intravenous Immune Therapy\nEstimat
 ed primary completion: 30 November 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07223424
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07061977-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07061977)
DESCRIPTION:Pembrolizumab\, phase 3\, Cervical Cancer.\nStudy: Induction Pe
 mbrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiati
 on and Pembrolizumab Maintenance Compared to Standard Chemoradiation With 
 Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical 
 Cancer\nEstimated primary completion: 31 December 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07061977
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06543576-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06543576)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Cervical Cancer.\nStudy: External B
 eam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherap
 y for the Treatment of Stage IVB Cervical Cancer\nEstimated primary comple
 tion: 31 January 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06543576
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06543576-2008@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06543576)
DESCRIPTION:Bevacizumab\, phase 1/2\, Cervical Cancer.\nStudy: External Bea
 m Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy 
 for the Treatment of Stage IVB Cervical Cancer\nEstimated primary completi
 on: 31 January 2031. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06543576
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06288373-1972@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20310301
DTEND;VALUE=DATE:20310302
SUMMARY:Camrelizumab: Phase 2/3 readout est. (NCT06288373)
DESCRIPTION:Camrelizumab\, phase 2/3\, Cervical Cancer.\nStudy: Neoadjuvant
  Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC\nEstimate
 d primary completion: 1 March 2031. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/camrelizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06288373
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07216703-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20311029
DTEND;VALUE=DATE:20311030
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07216703)
DESCRIPTION:Pembrolizumab\, phase 3\, Cervical Cancer.\nStudy: A Clinical S
 tudy of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizuma
 b (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-287
 0-036/TroFuse-036/GOG-3123/ENGOT-cx22)\nEstimated primary completion: 29 O
 ctober 2031. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07216703
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07216703-1991@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20311029
DTEND;VALUE=DATE:20311030
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT07216703)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Cervical Cancer.\nStudy: A 
 Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pe
 mbrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc
 er (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)\nEstimated primary comple
 tion: 29 October 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/sacituzumab-tirumotecan#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07216703
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07216703-2008@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20311029
DTEND;VALUE=DATE:20311030
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07216703)
DESCRIPTION:Bevacizumab\, phase 3\, Cervical Cancer.\nStudy: A Clinical Stu
 dy of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab 
 (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-
 036/TroFuse-036/GOG-3123/ENGOT-cx22)\nEstimated primary completion: 29 Oct
 ober 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 216703
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03755739-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20331101
DTEND;VALUE=DATE:20331102
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT03755739)
DESCRIPTION:Pembrolizumab\, phase 2/3\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus C
 hemodrug for Immunotherapy of Advanced Solid Tumors\nEstimated primary com
 pletion: 1 November 2033. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03755739
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770100-1973@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20400228
DTEND;VALUE=DATE:20400229
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07770100)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: C
 oncurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiat
 ion Therapy (SBRT) for Stage IV Cancers (COINSSS IV)\nEstimated primary co
 mpletion: 28 February 2040. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07770100
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
